A Pilot Bioequivalence Study of Pomalidomide

Inclusion Criteria: * Subjects should read, sign and date an Informed Consent Form and be fully informed of possible adverse events prior to any study procedures. * Subjects should complete the trial according to the regulations. * Subjects must agree to take effective contraceptive methods to prevent pregnancy from 2 weeks before screening until 3 months of last dose administration. Subjects must agree to avoid semen and blood donation until 3 months of last dose administration. * Healthy male volunteers of 18-50 years old. * Body mass index (BMI) ranges from 18.0 to 28.0 kg/m2, body weight ≥ 50 kg. * Medically healthy subjects with clinically normal Neutrophils and Platelets within 14 days. * No history of heart, liver, kidney, gastrointestinal tract diseases, nervous system, neural abnormities or metabolic abnormalities. Exclusion Criteria: * Smokers (\>3 cigarettes/day) * History of allergic reactions to pomalidomide or Thalidomide analogues. Any food allergies, which in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study. * Any history of thrombus or liver, kidney diseases. * History of Alcohol abuse (3990 ml beer, 1400 ml wine, 350 ml spirits/week) * Recent donation of plasma or significant loss of whole blood (\>400 ml) within 3 months. * Subjects have difficulty to swallow or any clinical significant history of ongoing gastrointestinal problems which affect absorption of drugs. * Received a prescription medicine wi…